Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 9/20 | 0.50 |
| ▸ | NOS1 | P29475 | 9/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | GRM5 | P41594 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6871648 | 0.99 | NOS3 (0.49) | NOS3NOS1MAOBGRM5CYP3A4 | |
| SCHEMBL6871642 | 0.98 | NOS3 (0.48) | NOS3NOS1MAOBGRM5CYP3A4 | |
| SCHEMBL5033273 | 0.94 | MAOB (0.52) | NOS3NOS1MAOBGRM5CYP3A4 | |
| SCHEMBL5519147 | 0.87 | MAOB (0.50) | NOS3NOS1MAOBGRM5MAPT | |
| SCHEMBL5513403 | 0.82 | MAPT (0.45) | NOS3NOS1MAOBGRM5CYP3A4 | |
| SCHEMBL5518354 | 0.82 | MRGPRX4 (0.49) | NOS3NOS1GRM5MAPTTSHR | |
| SCHEMBL5514957 | 0.82 | NOS3 (0.44) | NOS3NOS1 | |
| SCHEMBL5521356 | 0.80 | FFAR1 (0.47) | NOS3NOS1GRM5MAPTFFAR1 | |
| SCHEMBL5514672 | 0.80 | MAPT (0.51) | MAPT | |
| SCHEMBL5521555 | 0.80 | NCF1 (0.47) | NOS3NOS1MAOBCYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166589-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-01-23 | — | — | US | disclosed |
| CN-1289087-C | Quinoline derivatives as neuropeptide y antagonists | HOFFMANN LA ROCHE (CH) | 2006-12-13 | — | — | CN | disclosed |
| US-20060148794-A1 | Neuropeptide Y antagonist; antiarthritic agents; cardiovascular disorders; antidiabetic agents; kidney disorders; eating disorders; obesity | KLUG MICHAEL G | 2006-07-06 | — | — | US | disclosed |
| US-7064134-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060063758-A1 | Neuropeptide Y antagonist; antiarthritc agents; cardiovascular disorders; antidiabetic agents; kidney diseases; eating disorders; obesity | KLUG MICHAEL G | 2006-03-23 | — | — | US | disclosed |
| US-7012073-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-03-14 | — | — | US | disclosed |
| CN-1607951-A | Quinoline derivatives as neuropeptide y antagonists | HOFFMANN LA ROCHE (CH) | 2005-04-20 | — | — | CN | disclosed |
| US-20040259858-A1 | Quinoline derivatives | KLUG MICHAEL G (US) | 2004-12-23 | — | — | US | disclosed |
| US-6787558-B2 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS, FOR TREATING ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS AND OBESITY | HOFFMANN-LA ROCHE INC. | 2004-09-07 | — | — | US | disclosed |
| EP-1432421-A1 | QUINOLINE DERIVATIVES AS NEUROPEPTIDE Y ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2004-06-30 | — | — | EP | disclosed |
| US-20030158179-A1 | Quinoline derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2003-08-21 | — | — | US | disclosed |
| WO-2003028726-A1 | QUINOLINE DERIVATIVES AS NEUROPEPTIDE Y ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158179-A1 | Quinoline derivatives | RAB1A, GLS, REN | NOS3 497/4885NOS1 469/4885MAOB 1587/4885 |
| US-20060148794-A1 | Neuropeptide Y antagonist; antiarthritic agents; cardiovascular disorders; antidiabetic agents; kidney disorders; eating disorders; obesity | NPY1R, NPY2R, NPY4R | NOS3 513/4885NOS1 597/4885MAOB 1626/4885 |
| US-20040259858-A1 | Quinoline derivatives | RAB1A, GLS, REN | NOS3 497/4885NOS1 469/4885MAOB 1587/4885 |
| US-20060063758-A1 | Neuropeptide Y antagonist; antiarthritc agents; cardiovascular disorders; antidiabetic agents; kidney diseases; eating disorders; obesity | NPY1R, NPY2R, NPY4R | NOS3 434/4885NOS1 713/4885MAOB 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.